Lineage Cell Therapeutics
LCTX
74 hedge funds and large institutions have $99.9M invested in Lineage Cell Therapeutics in 2016 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 28 increasing their positions, 16 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
75% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 16
12% more funds holding
Funds holding: 66 → 74 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less capital invested
Capital invested by funds: $99.9M → $99.9M (-$39.5K)
0.9% less ownership
Funds ownership: 43.69% → 42.79% (-0.9%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $241K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$7.66M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.15M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$585K |
| 4 |
State Street
Boston,
Massachusetts
|
+$277K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$207K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$264K |
| 2 |
Jane Street
New York
|
-$229K |
| 3 |
Citigroup
New York
|
-$111K |
| 4 |
D.E. Shaw & Co
New York
|
-$104K |
| 5 |
FM
Family Management
New York
|
-$53.3K |
LCTX Hedge Fund Activity: Q2 2016 in Review
74 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2016, worth a combined $99.9M — down 0.04% from $99.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new LCTX positions and 3 closed out — a net gain of 8 holders — while 28 added to existing stakes and 16 trimmed.
The largest buyer was Broadwood Capital, adding an estimated $7.66M. The largest seller was Manatuck Hill Partners, cutting an estimated $264K.
- 74 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2016, up from 66 in Q1 2016.
- Funds reported $99.9M of Lineage Cell Therapeutics stock for Q2 2016, down 0.04% quarter-over-quarter.
- 11 funds opened new Lineage Cell Therapeutics positions in Q2 2016 and 3 closed out, a net change of +8 holders.
- The largest Lineage Cell Therapeutics buyer in Q2 2016 was Broadwood Capital, an estimated $7.66M added.
- The largest Lineage Cell Therapeutics seller in Q2 2016 was Manatuck Hill Partners, an estimated $264K sold.
Based on aggregated 13F filings for Q2 2016.